Thirty years of SET/TAF1β/I2PP2A: from the identification of the biological functions to its implications in cancer and Alzheimer’s disease
出版年份 2022 全文链接
标题
Thirty years of SET/TAF1β/I2PP2A: from the identification of the biological functions to its implications in cancer and Alzheimer’s disease
作者
关键词
-
出版物
BIOSCIENCE REPORTS
Volume 42, Issue 11, Pages -
出版商
Portland Press Ltd.
发表日期
2022-11-08
DOI
10.1042/bsr20221280
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Modulation of cellular processes by histone and non-histone protein acetylation
- (2022) Maria Shvedunova et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Inhibition of CK2 mitigates Alzheimer’s tau pathology by preventing NR2B synaptic mislocalization
- (2022) Courtney A. Marshall et al. Acta Neuropathologica Communications
- SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD–mutant AML
- (2021) Suruchi Pacharne et al. Blood Advances
- The interaction of SET and protein phosphatase 2A as target for cancer therapy
- (2021) E.C. Dacol et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- SET‐NUP214 and MLL cooperatively regulate the promoter activity of the HoxA10 gene
- (2021) Sadik Cigdem et al. GENES TO CELLS
- Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response
- (2021) Yu-Ting Yen et al. Nature Communications
- Phosphoproteome and drug response effects mediated by the three Protein Phosphatase 2A inhibitor proteins CIP2A, SET and PME-1
- (2020) Otto Kauko et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer’s Disease Pathogenesis in Cell and Animal Models
- (2020) Hui Wei et al. Neurotherapeutics
- A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia
- (2020) Elena Arriazu et al. Blood Cancer Journal
- SET SUMOylation promotes its cytoplasmic retention and induces tau pathology and cognitive impairments
- (2019) Min Qin et al. Acta Neuropathologica Communications
- Loss of SET reveals both the p53-dependent and the p53-independent functions in vivo
- (2019) Ning Kon et al. Cell Death & Disease
- The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction
- (2019) Ryan M. De Palma et al. FASEB JOURNAL
- Post‐translational regulation could determine functional differences between SET alpha and beta isoforms in chronic lymphocytic leukaemia
- (2019) Ion Cristóbal et al. BRITISH JOURNAL OF HAEMATOLOGY
- Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer
- (2019) Ion Cristóbal et al. Journal of Clinical Medicine
- Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia”
- (2019) Danilo Perrotti et al. Science Translational Medicine
- Aurora B kinase activity is regulated by SET/TAF1 on Sgo2 at the inner centromere
- (2019) Yuichiro Asai et al. JOURNAL OF CELL BIOLOGY
- Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer
- (2018) Otto Kauko et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis
- (2018) Shuhei Enjoji et al. MOLECULAR CANCER RESEARCH
- SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub
- (2018) Rocco Piazza et al. Nature Communications
- A comprehensive and perspective view of oncoprotein SET in cancer
- (2018) Buuvee Bayarkhangai et al. Cancer Medicine
- CK2 Phosphorylating I2PP2A/SET Mediates Tau Pathology and Cognitive Impairment
- (2018) Qing Zhang et al. Frontiers in Molecular Neuroscience
- Targeting PP2A in cancer: Combination therapies
- (2018) Sahar Mazhar et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back
- (2018) Jukka Westermarck FEBS Journal
- How it all Started: Tau and Protein Phosphatase 2A
- (2018) Chang Liu et al. JOURNAL OF ALZHEIMERS DISEASE
- p53 Function is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma
- (2018) Yun Wei et al. MOLECULAR CANCER RESEARCH
- SET Oncogene is Upregulated in Pediatric Acute Lymphoblastic Leukemia
- (2018) Sema Sirma Ekmekci et al. TUMORI
- SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment
- (2018) Yu-Hsiang Huang et al. Journal of Clinical Medicine
- SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia
- (2018) Danielle M. Brander et al. BRITISH JOURNAL OF HAEMATOLOGY
- SET/I2PP2A overexpression induces phenotypic, molecular, and metabolic alterations in an oral keratinocyte cell line
- (2017) Lays M. Sobral et al. FEBS Journal
- Protein phosphatase 2A and tau: an orchestrated ‘Pas de Deux’
- (2017) Goce Taleski et al. FEBS LETTERS
- PP32 and SET/TAF-Iβ proteins regulate the acetylation of newly synthesized histone H4
- (2017) Francisco Saavedra et al. NUCLEIC ACIDS RESEARCH
- Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer
- (2017) Xiaoning Yuan et al. ONCOLOGY REPORTS
- SET oncoprotein accumulation regulates transcription through DNA demethylation and histone hypoacetylation
- (2017) Luciana O. Almeida et al. Oncotarget
- The role of SET/I2PP2A in canine mammary tumors
- (2017) Satoru Kake et al. Scientific Reports
- The zebrafish homologs of SET/I2PP2A oncoprotein: expression patterns and insights into their physiological roles during development
- (2016) I. Serifi et al. BIOCHEMICAL JOURNAL
- Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode
- (2016) Donglai Wang et al. NATURE
- Histone chaperone activity of Arabidopsis thaliana NRP1 is blocked by cytochrome c
- (2016) Katiuska González-Arzola et al. NUCLEIC ACIDS RESEARCH
- MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia
- (2016) Raffaella Pippa et al. Oncotarget
- Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia
- (2016) Nameeta P. Richard et al. Oncotarget
- Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia
- (2016) Elena Arriazu et al. Frontiers in Oncology
- All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase
- (2015) Jaya Sangodkar et al. FEBS Journal
- Cross talk between PI3K-AKT-GSK-3β and PP2A pathways determines tau hyperphosphorylation
- (2015) Yixuan Wang et al. NEUROBIOLOGY OF AGING
- Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer
- (2015) Hao Liu et al. Oncotarget
- PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
- (2015) Raúl Rincón et al. Oncotarget
- The Nuclear Oncogene SET Controls DNA Repair by KAP1 and HP1 Retention to Chromatin
- (2015) Alkmini Kalousi et al. Cell Reports
- Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia
- (2015) Kavitha Ramaswamy et al. Frontiers in Oncology
- From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies
- (2015) Maria Ciccone et al. Frontiers in Oncology
- SET-NUP214 is a recurrent lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL
- (2014) R. Ben Abdelali et al. BLOOD
- Cytoplasmic SET induces tau hyperphosphorylation through a decrease of methylated phosphatase 2A
- (2014) Stéphanie Chasseigneaux et al. BMC NEUROSCIENCE
- Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
- (2014) A. Agarwal et al. CLINICAL CANCER RESEARCH
- Inhibition of FoxO1 acetylation by INHAT subunit SET/TAF-Iβ induces p21 transcription
- (2014) Yun-Cheol Chae et al. FEBS LETTERS
- Cytoplasmic Retention of Protein Phosphatase 2A Inhibitor 2 (I2PP2A) Induces Alzheimer-like Abnormal Hyperphosphorylation of Tau
- (2014) Mohammad Arif et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity
- (2014) R Pippa et al. LEUKEMIA
- Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models
- (2014) Lays M Sobral et al. Molecular Cancer
- Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer
- (2014) Amy S. Farrell et al. MOLECULAR CANCER RESEARCH
- PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential
- (2014) I. Cristobal et al. MOLECULAR CANCER THERAPEUTICS
- Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer
- (2014) M. Janghorban et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Protein phosphatase 2A dysfunction in Alzheimer’s disease
- (2014) Jean-Marie Sontag et al. Frontiers in Molecular Neuroscience
- Alzheimer disease and amyotrophic lateral sclerosis: an etiopathogenic connection
- (2013) Xiaochuan Wang et al. ACTA NEUROPATHOLOGICA
- Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies
- (2013) J. J. Oaks et al. BLOOD
- Inhibition of Ku70 acetylation by INHAT subunit SET/TAF-Iβ regulates Ku70-mediated DNA damage response
- (2013) Kee-Beom Kim et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
- (2013) Paolo Neviani et al. JOURNAL OF CLINICAL INVESTIGATION
- Protein phosphatase 2A: a target for anticancer therapy
- (2013) Danilo Perrotti et al. LANCET ONCOLOGY
- Silencing PP2A Inhibitor by Lenti-shRNA Interference Ameliorates Neuropathologies and Memory Deficits in tg2576 Mice
- (2013) Gong-Ping Liu et al. MOLECULAR THERAPY
- Somatic SETBP1 mutations in myeloid malignancies
- (2013) Hideki Makishima et al. NATURE GENETICS
- Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease
- (2013) Guang Yu et al. NEUROBIOLOGY OF AGING
- SET translocation is associated with increase in caspase cleaved amyloid precursor protein in CA1 of Alzheimer and Down syndrome patients
- (2013) Patricia Facchinetti et al. NEUROBIOLOGY OF AGING
- Tau protein kinases: Involvement in Alzheimer's disease
- (2012) Ludovic Martin et al. AGEING RESEARCH REVIEWS
- Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis
- (2012) Sahar A. Saddoughi et al. EMBO Molecular Medicine
- SET overexpression decreases cell detoxification efficiency: ALDH2 and GSTP1 are downregulated, DDR is impaired and DNA damage accumulates
- (2012) Luciana O. Almeida et al. FEBS Journal
- H3K27 methylation and H3S28 phosphorylation-dependent transcriptional regulation by INHAT subunit SET/TAF-Iβ
- (2012) Ji-Young Kim et al. FEBS LETTERS
- Cytoplasmic targeting of the proto-oncogene SET promotes cell spreading and migration
- (2012) B. Daniel Lam et al. FEBS LETTERS
- The Apolipoprotein-E-Mimetic COG112 Protects Amyloid Precursor Protein Intracellular Domain-Overexpressing Animals from Alzheimer's Disease-Like Pathological Features
- (2012) Kaushik Ghosal et al. Neurodegenerative Diseases
- Phenotypic and genetic characterization of adult T-cell acute lymphoblastic leukemia with del(9)(q34);SET-NUP214 rearrangement
- (2011) Hyojin Chae et al. ANNALS OF HEMATOLOGY
- SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target
- (2011) D. J. Christensen et al. BLOOD
- Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2PP2A/SET
- (2011) Lisette Arnaud et al. FEBS LETTERS
- Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia
- (2011) I. Cristobal et al. HAEMATOLOGICA
- PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect
- (2011) I Cristóbal et al. LEUKEMIA
- Inhibition of Protein Phosphatase 2A Activity by PI3Kγ Regulates β-Adrenergic Receptor Function
- (2011) Neelakantan T. Vasudevan et al. MOLECULAR CELL
- Inhibition of p53 acetylation by INHAT subunit SET/TAF-Iβ represses p53 activity
- (2011) Ji-Young Kim et al. NUCLEIC ACIDS RESEARCH
- Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy
- (2011) C H Switzer et al. ONCOGENE
- The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells
- (2010) R. Trotta et al. BLOOD
- The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment
- (2010) Xiaochuan Wang et al. FASEB JOURNAL
- Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance
- (2010) Suriyan Ponnusamy et al. Future Oncology
- SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia
- (2009) I. Cristobal et al. BLOOD
- Identification of distinct SET/TAF-Iβ domains required for core histone binding and quantitative characterisation of the interaction
- (2009) Zoe Karetsou et al. BMC BIOCHEMISTRY
- SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines
- (2009) Hilmar Quentmeier et al. Journal of Hematology & Oncology
- The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia
- (2008) P. Van Vlierberghe et al. BLOOD
- Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling
- (2008) Archana Mukhopadhyay et al. FASEB JOURNAL
- Activated glucocorticoid receptor interacts with the INHAT component Set/TAF-Iβ and releases it from a glucocorticoid-responsive gene promoter, relieving repression: Implications for the pathogenesis of glucocorticoid resistance in acute undifferentiated leukemia with Set-Can translocation
- (2007) Takamasa Ichijo et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Activation of glycogen synthase kinase-3 inhibits protein phosphatase-2A and the underlying mechanisms
- (2007) Gong-Ping Liu et al. NEUROBIOLOGY OF AGING
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started